DEA Update on Scheduling Synthetic Cannabinoids in Schedule I
The DEA scheduling synthetic cannabinoids update highlights the placement of four novel compounds into Schedule I. These synthetic cannabinoids pose significant public health risks due to their high potency and unknown safety profiles. Clinicians should…
DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
The DEA has placed 4-fluoroamphetamine into Schedule I, recognizing it as a synthetic amphetamine analog with high abuse potential. This 4-fluoroamphetamine schedule I classification highlights regulatory efforts to control novel psychoactive substances.…
Top Issues in Cannabis Industry 2026: Hemp Redefinition & Market Changes
Cannabis hemp redefinition 2026 will reclassify popular hemp products as Schedule I substances, impacting legality and banking. This shift tightens regulations and market access. Understanding these changes is crucial for industry stakeholders.